The Future of Lipid-Lowering Therapy

The recent introduction of inhibitors of proprotein convertase subtilisin/kexin 9 to lower low-density lipoprotein (LDL) cholesterol on top of statins or as monotherapy is rapidly changing the landscape of treatment of atherosclerotic cardiovascular disease (ASCVD). However, existing lipid-lowering...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zwol, Willemien, Rimbert, Antoine, Kuivenhoven, Jan Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678580/
https://www.ncbi.nlm.nih.gov/pubmed/31340607
http://dx.doi.org/10.3390/jcm8071085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678580/
https://www.ncbi.nlm.nih.gov/pubmed/31340607
http://dx.doi.org/10.3390/jcm8071085

Ejemplares similares